{"id":"NCT02267226","sponsor":"Octapharma","briefTitle":"Efficacy and Safety Study of Octafibrin for On-demand Treatment of Acute Bleeding and to Prevent Bleeding During and After Surgery","officialTitle":"Prospective, Open-label, Uncontrolled, Phase III Study to Assess the Efficacy and Safety of Octafibrin for On-demand Treatment of Acute Bleeding and to Prevent Bleeding During and After Surgery in Subjects With Congenital Fibrinogen Deficiency","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-09","primaryCompletion":"2018-02-14","completion":"2018-02-14","firstPosted":"2014-10-17","resultsPosted":"2019-02-20","lastUpdate":"2021-01-15"},"enrollment":25,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Congenital Fibrinogen Deficiency"],"interventions":[{"type":"DRUG","name":"Octafibrin","otherNames":[]}],"arms":[{"label":"Octafibrin","type":"EXPERIMENTAL"}],"summary":"The purpose of the study is to assess the efficacy and safety of Octafibrin for on-demand treatment of acute bleeding in subjects with congenital fibrinogen deficiency.","primaryOutcome":{"measure":"Overall Clinical Assessment of the Haemostatic Efficacy of Octafibrin in Treating the First Documented Bleeding Episode of Each Patient.","timeFrame":"24 hours after last infusion for each bleeding episode","effectByArm":[{"arm":"Investigator Assessment","deltaMin":19,"sd":null},{"arm":"IDMEAC Assessment","deltaMin":23,"sd":null}],"pValues":[]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":13},"locations":{"siteCount":12,"countries":["United States","Bulgaria","India","Iran","Lebanon","Russia","Saudi Arabia","Turkey (TÃ¼rkiye)","United Kingdom"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":25},"commonTop":["Limb injury","Pain in extremity","Gingival bleeding","Vomiting","Hypertension"]}}